(VIR) Vir Biotechnology - Ratings and Ratios

Vir Biotechnology, Inc. (NASDAQ:VIR) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address serious infectious diseases. The companys pipeline includes clinical-stage investigational therapies targeting hepatitis delta virus (HDV) and solid tumors. Its preclinical candidates address a range of pathogens, including influenza A and B, COVID-19, respiratory syncytial virus (RSV), human metapneumovirus (MPV), and human papillomavirus (HPV). Vir has established strategic partnerships, including grant agreements with the Bill & Melinda Gates Foundation, a collaboration with Alnylam Pharmaceuticals, and license agreements with MedImmune and Sanofi. The company also has a research collaboration with GlaxoSmithKline Biologicals S.A. Vir Biotechnology was founded in 2016 and is headquartered in San Francisco, California.

Based on the provided data, Vir Biotechnologys stock is currently trading at $6.15, with a 20-day average volume of 971,569 shares. The stocks short-term trend, indicated by the SMA 20 at $5.79, suggests recent upward momentum, while the SMA 50 at $6.72 and SMA 200 at $8.13 reflect a longer-term downtrend. The ATR of 0.41 indicates moderate volatility. Fundamentally, the company has a market cap of $839.43M, a forward P/E of 4.36, and a price-to-book ratio of 0.73, suggesting potential undervaluation. However, the negative return on equity (-38.86%) raises concerns about profitability. Overall, while the stock shows short-term strength, long-term performance will depend on the success of its pipeline and strategic collaborations.